Laboratory of Mycobacterial Diseases and Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA.
Infect Immun. 2013 Feb;81(2):585-97. doi: 10.1128/IAI.01249-12. Epub 2012 Dec 10.
We employed Francisella tularensis live vaccine strain (LVS) to study mechanisms of protective immunity against intracellular pathogens and, specifically, to understand protective correlates. One potential molecular correlate identified previously was interleukin-6 (IL-6), a cytokine with pleotropic roles in immunity, including influences on T and B cell functions. Given its role as an immune modulator and the correlation with successful anti-LVS vaccination, we examined the role IL-6 plays in the host response to LVS. IL-6-deficient (IL-6 knockout [KO]) mice infected with LVS intradermally or intranasally or anti-IL-6-treated mice, showed greatly reduced 50% lethal doses compared to wild-type (WT) mice. Increased susceptibility was not due to altered splenic immune cell populations during infection or decreased serum antibody production, as IL-6 KO mice had similar compositions of each compared to WT mice. Although LVS-infected IL-6 KO mice produced much less serum amyloid A and haptoglobin (two acute-phase proteins) than WT mice, there were no other obvious pathophysiological differences between LVS-infected WT and IL-6 KO mice. IL-6 KO or WT mice that survived primary LVS infection also survived a high-dose LVS secondary challenge. Using an in vitro overlay assay that measured T cell activation, cytokine production, and abilities of primed splenocytes to control intracellular LVS growth, we found that IL-6 KO total splenocytes or purified T cells were slightly defective in controlling intracellular LVS growth but were equivalent in cytokine production. Taken together, IL-6 is an integral part of a successful immune response to primary LVS infection, but its exact role in precipitating adaptive immunity remains elusive.
我们使用了减毒活疫苗株(LVS)弗朗西斯氏菌来研究针对细胞内病原体的保护性免疫机制,特别是要了解保护性相关因素。先前确定的一个潜在的分子相关因素是白细胞介素-6(IL-6),这是一种具有多种免疫作用的细胞因子,包括对 T 和 B 细胞功能的影响。鉴于其作为免疫调节剂的作用以及与成功抗 LVS 疫苗接种的相关性,我们研究了 IL-6 在宿主对 LVS 反应中的作用。经皮内或鼻内感染 LVS 或接受抗 IL-6 治疗的 IL-6 缺陷(IL-6 敲除 [KO])小鼠与野生型(WT)小鼠相比,50%致死剂量大大降低。敏感性增加不是由于感染期间脾脏免疫细胞群的改变或血清抗体产生减少所致,因为与 WT 小鼠相比,IL-6 KO 小鼠具有相似的组成。尽管 LVS 感染的 IL-6 KO 小鼠产生的血清淀粉样蛋白 A 和触珠蛋白(两种急性期蛋白)比 WT 小鼠少得多,但 LVS 感染的 WT 和 IL-6 KO 小鼠之间没有其他明显的病理生理差异。初次 LVS 感染后存活的 IL-6 KO 或 WT 小鼠也能在高剂量 LVS 二次攻击中存活。使用一种测量 T 细胞活化、细胞因子产生以及用致敏脾细胞控制细胞内 LVS 生长的体外覆盖测定法,我们发现 IL-6 KO 总脾细胞或纯化的 T 细胞在控制细胞内 LVS 生长方面略有缺陷,但在细胞因子产生方面则相当。总之,IL-6 是成功应对初次 LVS 感染的免疫反应的一个组成部分,但它在引发适应性免疫方面的确切作用仍不清楚。